The approval of anti-cholesterol therapy Praluent (alirocumab) from Regeneron Pharmaceuticals Inc. and Sanofi SA heralds a change "equivalent to the statin revolution in terms of lipid management," Katherine Wilemon, founder of the Familial Hypercholesterolemia (FH) Foundation, told BioWorld Today.